Yuyu Pharma, Inc. (KRX:000220)
South Korea
· Delayed Price · Currency is KRW 4,645.00
0.00 (0.00%)
At close: Apr 17, 2025, 3:30 PM KST
Yuyu Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Other Revenue | -0 | -0 | -0 | - | 0 | Upgrade
|
| Revenue | 133,147 | 137,210 | 138,881 | 115,655 | 98,120 | Upgrade
|
| Revenue Growth (YoY) | -2.96% | -1.20% | 20.08% | 17.87% | 7.97% | Upgrade
|
| Cost of Revenue | 81,778 | 88,682 | 85,915 | 70,567 | 52,965 | Upgrade
|
| Gross Profit | 51,369 | 48,527 | 52,966 | 45,088 | 45,155 | Upgrade
|
| Selling, General & Admin | 34,190 | 37,972 | 43,028 | 37,270 | 32,464 | Upgrade
|
| Research & Development | 2,780 | 7,188 | 8,620 | 4,008 | 4,123 | Upgrade
|
| Other Operating Expenses | 212.88 | 219.22 | 221.25 | 258.87 | 196.61 | Upgrade
|
| Operating Expenses | 38,788 | 49,276 | 53,559 | 43,888 | 38,884 | Upgrade
|
| Operating Income | 12,582 | -748.94 | -592.11 | 1,200 | 6,271 | Upgrade
|
| Interest Expense | -3,218 | -2,554 | -2,581 | -2,175 | -1,759 | Upgrade
|
| Interest & Investment Income | 1,066 | 990.69 | 605.88 | 216.83 | 210.32 | Upgrade
|
| Earnings From Equity Investments | 68.58 | -493.69 | 395.07 | 548.18 | 286.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -150.09 | -23.86 | -478.12 | 56.72 | -198.24 | Upgrade
|
| Other Non Operating Income (Expenses) | -892.12 | -2,592 | -852.87 | -87.18 | -1,217 | Upgrade
|
| EBT Excluding Unusual Items | 9,456 | -5,422 | -3,503 | -240.68 | 3,593 | Upgrade
|
| Gain (Loss) on Sale of Investments | -370.71 | 657.78 | 182.69 | -139.24 | -110.35 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1,249 | 63.45 | -46.08 | -3.23 | 282.15 | Upgrade
|
| Asset Writedown | -349.46 | -741.5 | -444.09 | - | -53.65 | Upgrade
|
| Pretax Income | 9,985 | -5,442 | -3,810 | -383.16 | 3,711 | Upgrade
|
| Income Tax Expense | -304.67 | 98.44 | 615.02 | 537.13 | 1,299 | Upgrade
|
| Earnings From Continuing Operations | 10,289 | -5,541 | -4,425 | -920.29 | 2,413 | Upgrade
|
| Minority Interest in Earnings | -1,569 | -1,640 | -1,562 | -1,294 | -1,129 | Upgrade
|
| Net Income | 8,720 | -7,181 | -5,988 | -2,214 | 1,284 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1,145 | -878.27 | 284.89 | 284.89 | 284.89 | Upgrade
|
| Net Income to Common | 7,575 | -6,303 | -6,273 | -2,499 | 998.63 | Upgrade
|
| Net Income Growth | - | - | - | - | -72.82% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 17 | 16 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 16 | 17 | 16 | 12 | Upgrade
|
| Shares Change (YoY) | 3.29% | -1.89% | 3.90% | 32.81% | -19.87% | Upgrade
|
| EPS (Basic) | 468.10 | -387.43 | -378.31 | -156.57 | 83.10 | Upgrade
|
| EPS (Diluted) | 462.90 | -387.43 | -378.31 | -157.00 | 83.00 | Upgrade
|
| EPS Growth | - | - | - | - | -77.94% | Upgrade
|
| Free Cash Flow | 17,838 | -4,094 | -11,512 | -1,565 | -14,716 | Upgrade
|
| Free Cash Flow Per Share | 1061.56 | -251.63 | -694.28 | -98.04 | -1224.65 | Upgrade
|
| Gross Margin | 38.58% | 35.37% | 38.14% | 38.98% | 46.02% | Upgrade
|
| Operating Margin | 9.45% | -0.55% | -0.43% | 1.04% | 6.39% | Upgrade
|
| Profit Margin | 5.69% | -4.59% | -4.52% | -2.16% | 1.02% | Upgrade
|
| Free Cash Flow Margin | 13.40% | -2.98% | -8.29% | -1.35% | -15.00% | Upgrade
|
| EBITDA | 18,248 | 4,858 | 4,435 | 5,703 | 10,170 | Upgrade
|
| EBITDA Margin | 13.71% | 3.54% | 3.19% | 4.93% | 10.37% | Upgrade
|
| D&A For EBITDA | 5,666 | 5,607 | 5,027 | 4,503 | 3,899 | Upgrade
|
| EBIT | 12,582 | -748.94 | -592.11 | 1,200 | 6,271 | Upgrade
|
| EBIT Margin | 9.45% | -0.55% | -0.43% | 1.04% | 6.39% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 34.99% | Upgrade
|
| Advertising Expenses | 2,695 | 4,481 | 7,119 | 6,131 | 4,382 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.